| Abstract P091 – Table 1. Results from multivariable analyses on effectiveness to initial ART and treatment discontinuations due to AEs. | |||||
|---|---|---|---|---|---|
| Treatment discontinuations due to AEs | Immunological response | Immunological response | Viral suppression | Viral suppression | |
| Adjusted mean difference (95% CI)a | Adjusted mean difference (95% CI)a | Adjusted OR (95% CI)a | Adjusted OR (95% CI)a | ||
| 24 weeks (n = 1288) | 48 weeks (n = 951) | 24 weeks (n = 1040) | 48 weeks (n = 715) | ||
| 3TC/DTG (n = 234, 15.35%) | 1 (0.4%) | Ref. | Ref. | Ref. | Ref. |
| TAF/FTC/BIC (n = 580, 38.06%) | 9 (1.5%) | 30.05 (‐3.99 to 64.09) | 21.19 (‐18.33 to 60.72) | 1.23 (0.80 to 1.88) | 0.73 (0.23 to 2.30) |
| ABC/3TC/DTG (n = 229, 15.03%) | 7 (3.1%) | 26.68 (‐10.11 to 63.47) | 25.7 (‐22.52 to 73.86) | 1.08 (0.56 to 2.11) | 0.78 (0.26 to 2.37) |
| TAF/FTC+DRV/COBI (n = 127, 8.33%) | 3 (2.4%) | 3.89 (‐42.89 to 50.68) | 3.20 (‐59.42 to 65.81) | 0.55 (0.34 to 0.89) | 0.63 (0.17 to 2.25) |
| TAF/FTC/EVG/COBI (n = 120, 7.87%) | 7 (5.8%) | 14.72 (‐28.56 to 58.00) | 41.386 (‐5.00 to 87.77) | 1.11 (0.53 to 2.34) | 1.97 (0.48 to 8.04) |
| TDF/FTC+DTG (n = 234, 15.35%) | 19 (8.1%) | 43.13 (‐9.81 to 96.07) | 35.39 (‐28.63 to 99.40) | 1.27 (0.61 to 2.63) | 0.95 (0.26 to 3.50) |
| Overall p‐value | <0.001 | 0.381 | 0.213 | 0.006 | 0.424 |
3TC, lamivudine; ABC, abacavir; BIC, bictegravir; COBI, cobicistat; DRV, darunavir; DTG, dolutegavir; FTC, emtricitabine; TAF, tenofovir alafenamide; TDF, tenofovir.
aAdjusted by sex, age at ART initiation, transmission category, educational level, country of origin, CD4 T‐cell count and viral load within 6 months prior to ART initiation, presence of hepatitis C virus antibodies, presence of hepatitis B virus surface antigen and AIDS diagnosis at start of ART.